Celldex Therapeutics Total Assets 2010-2023 | CLDX
Celldex Therapeutics total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
Celldex Therapeutics Annual Total Assets
(Millions of US $) |
| 2022 |
$353 |
| 2021 |
$445 |
| 2020 |
$236 |
| 2019 |
$123 |
| 2018 |
$156 |
| 2017 |
$316 |
| 2016 |
$383 |
| 2015 |
$338 |
| 2014 |
$248 |
| 2013 |
$347 |
| 2012 |
$126 |
| 2011 |
$98 |
| 2010 |
$110 |
| 2009 |
$140 |
Celldex Therapeutics Quarterly Total Assets
(Millions of US $) |
| 2023-03-31 |
$325 |
| 2022-12-31 |
$353 |
| 2022-09-30 |
$369 |
| 2022-06-30 |
$403 |
| 2022-03-31 |
$424 |
| 2021-12-31 |
$445 |
| 2021-09-30 |
$460 |
| 2021-06-30 |
$205 |
| 2021-03-31 |
$219 |
| 2020-12-31 |
$236 |
| 2020-09-30 |
$256 |
| 2020-06-30 |
$261 |
| 2020-03-31 |
$113 |
| 2019-12-31 |
$123 |
| 2019-09-30 |
$132 |
| 2019-06-30 |
$142 |
| 2019-03-31 |
$148 |
| 2018-12-31 |
$156 |
| 2018-09-30 |
$168 |
| 2018-06-30 |
$178 |
| 2018-03-31 |
$191 |
| 2017-12-31 |
$316 |
| 2017-09-30 |
$319 |
| 2017-06-30 |
$346 |
| 2017-03-31 |
$360 |
| 2016-12-31 |
$383 |
| 2016-09-30 |
$252 |
| 2016-06-30 |
$271 |
| 2016-03-31 |
$302 |
| 2015-12-31 |
$338 |
| 2015-09-30 |
$353 |
| 2015-06-30 |
$383 |
| 2015-03-31 |
$408 |
| 2014-12-31 |
$248 |
| 2014-09-30 |
$272 |
| 2014-06-30 |
$298 |
| 2014-03-31 |
$319 |
| 2013-12-31 |
$347 |
| 2013-09-30 |
$181 |
| 2013-06-30 |
$196 |
| 2013-03-31 |
$224 |
| 2012-12-31 |
$126 |
| 2012-09-30 |
$120 |
| 2012-06-30 |
$122 |
| 2012-03-31 |
$137 |
| 2011-12-31 |
$98 |
| 2011-09-30 |
$108 |
| 2011-06-30 |
$118 |
| 2011-03-31 |
$92 |
| 2010-12-31 |
$110 |
| 2010-09-30 |
$112 |
| 2010-06-30 |
$122 |
| 2010-03-31 |
$132 |
| 2009-12-31 |
$140 |
| 2009-09-30 |
$48 |
| 2009-06-30 |
$54 |
| 2009-03-31 |
$63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.518B |
$0.002B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
